Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group (Q71120796)
scientific article published on 01 June 1996
Language:
(P31) (Q13442814)
(P304) 1354-1366
(P407) (Q1860)
(P433) 6
(P478) 173
(P577) Saturday, June 1, 1996
(P921) (Q422606)
(Q198504)
(P1104) 13
(P1433) (Q4051141)
(P1476) "Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group" (language: en)
(P2093) R T Schooley
C Ramirez-Ronda
J M Lange
D A Cooper
J Lavelle
L Lefkowitz
M Moore
B A Larder
M St Clair
J W Mulder
R McKinnis
K N Pennington
P R Harrigan
I Kinghorn
H Steel
J F Rooney
other details
description scientific article published on 01 June 1996

External Links